In NRAS-mutant melanoma, scRNA-seq revealed rapid upregulation of the purinergic receptor P2RX7 within 72 h of MEK/CDK4/6 inhibition, promoting survival via calcium influx (Randic et al., 2023). The gene discussed is P2RX7; the disease is melanoma.